May. 7 at 11:14 PM
$PTCT Very interesting, NLRP3 is rapidly emerging as an important and clinically validated target. Ventyx and Bioage got to about 1b valuation on early clinical data for NLRP3 inhibitors. PTC can get similar clinical data within a year: 'In the second quarter, we expect to initiate the Phase I study of PTC612, our oral NLRP3 inhibitor. While the majority of the study will be conducted in healthy volunteers, we will look to include a dosing cohort of individuals with elevated inflammatory biomarkers to enable an early assessment of PK/PD. As we have discussed, PTC612 benchmarks favorably to other NLRP3 inhibitors in terms of potency. We expect to develop PTC612 for inflammatory lung disorders where there is overlap between the NLRP3 inflammasome and disease pathology'. (Matthew Klein on Q1 call).
